FUTURA MEDICAL PLC

Board/Management Information • Dec 3, 2025

National Storage Mechanism | Additional information

RNS Number : 9582J

Futura Medical PLC

03 December 2025

03 December 2025

Futura Medical plc

("Futura", "the Group" or the "Company")

Board change

Futura Medical (AIM:FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that following the passing of resolutions in respect to the recently announced placing and subscription, and significant reduction in Lombard Odier Asset Management's percentage shareholding in Futura following the upcoming admission of the placing shares and subscription shares to trading on AIM, Harmesh Suniara is stepping down from his role as Non-Executive Director and will step off the Board with immediate effect. Harmesh was appointed to the Board as Lombard Odier Asset Management's representative in March 2025.

Andrew Unitt, Non-Executive Chair, commented: "The Board would like to express our gratitude to Harmesh for his dedication to the Company during his tenure as Non-Executive Director; his advice and guidance have been invaluable ahead of the completion of the fundraise. With the successful fundraising in place giving the Company a sure financial footing, we are now focused on the competition of the strategic review in Q1 FY26, alongside progressing the development of Eroxon Intense and WSD4000."

Contacts:

Futura Medical plc	Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO	[email protected] +44 (0)1483 685 670 www.futuramedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0)20 3100 2000
Turner Pope Investments (TPI) Ltd Broker	Guy McDougall / Andrew Thacker	+44 (0) 20 3657 0050
Alma Strategic Communications	Rebecca Sanders-Hewett Sam Modlin Emma Thompson	+44 (0)20 3405 0205 [email protected]

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of  ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOATTBRTMTTMBJA